| Name | Title | Contact Details |
|---|
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body`s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.
Cleveland Diagnostics is developing a breakthrough technology to discover a new class of diagnostics tests with high sensitivity and specificity for many cancers – early on, when cancer is still curable.
A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors.
Nutripro Biosystems, Inc is a Worthington, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Geltor is the bio-design company that makes the world`s most advanced proteins for consumers, with a focus on unique functionality and sustainability.